Perspective: Life sciences in peril
The unintended consequences of legislation are often as important as the original purpose. Two bills scheduled to be considered next month by the U.S. Senate’s Committee on Health, Education, Labor, and Pensions (HELP) are well-intentioned but would undermine Colorado’s thriving life sciences industry, interfere with the drug discovery pipeline and potentially risk patient safety.
Each bill aims to streamline part of the federal government’s drug approval process — a worthy goal. But each one misses the mark, and would cause serious consequences for patients and our region’s economy.
The first bill, the Medication Affordability and Patent Integrity Act, is a solution in search of a problem. It assumes that government agencies lack sufficient information about new prescription drugs. Yet the United States has one of the most thorough drug approval processes in the world, which has made it a global leader in patient safety and pharmaceutical development.
No one familiar with the documentation requirements of the Food and Drug Administration (FDA) for new drug applications — which typically run to 100,000 pages — seriously believes that they don’t involve enough paperwork. Yet the legislation would require drug companies to also disclose confidential trade secrets to the U.S. Patent and Trademark Office.
At a minimum, this would throw additional regulatory roadblocks in front of bioscience companies, like those in the Denver-Boulder region, and lead to slower approval of patents and thus slower delivery of new drugs to patients. Burdensome new disclosure requirements would force these firms — which are often startups with limited resources — to divert funds from critical research activities to ensure legal compliance.
Additionally, it would put U.S. trade secrets at much greater risk of being pilfered by our global adversaries. Drug formulations and manufacturing processes are highly sensitive information, which is why the FDA keeps them strictly confidential. Bad actors like China work assiduously to steal these secrets so they can avoid the hefty costs associated with research and development. In fact, the FBI estimates that Chinese theft of U.S. intellectual property across every sector costs our economy up to $600 billion each year.
Forcing Colorado biotech firms to submit their sensitive data to the U.S. Patent and Trademark Office dramatically increases the risk that such information will fall into the hands of China and other copycats. Unlike the FDA, the U.S. Patent and Trademark Office operates under mandatory public disclosure requirements — meaning that it’s practically a guarantee these trade secrets would get exposed.
The proposal would also debilitate the U.S. Patent and Trademark Office — and in turn, the patent process. As of July, the agency had almost 800,000 patent applications pending review. There is no justification for saddling the agency with more data beyond its administrative capacity or scope of expertise. Its staff are not trained to assess drugs’ clinical profiles like specialists at the FDA. If the U.S. Patent and Trademark Office is required to add complex pharmaceutical information to its analysis portfolio, it will become even more inefficient — leaving Colorado’s medical innovators in a state of paralysis.
Medical breakthroughs, even life-saving cancer therapies, would languish on government desks and might never reach patients in need of them as soon as the FDA approves them.
The second bill, the Biosimilar Red Tape Elimination Act, is another well-intentioned but poorly conceived attempt to increase patient access to lower-cost “biosimilar” drugs.
Biosimilars are copycat versions of sophisticated biologic drugs, which are made from live organisms and typically infused or injected. Just as generics mimic name-brand oral medicines, biosimilars mimic name-brand biologics. Unlike generics, however, which are exactly the same as the original drug, a biosimilar is “highly similar to a reference product,” says the FDA (the reference product is the original biologic).
A biosimilar can also be approved as “interchangeable” — a precise legal designation — which means switching between the original biologic and the interchangeable biosimilar would not increase safety risks or decrease effectiveness. To see if a biosimilar meets that standard, and is truly interchangeable, manufacturers may submit additional information to the FDA to ensure patient safety. If the FDA then determines the biosimilar is interchangeable, pharmacists may substitute it in place of the reference drug without consulting a patient’s physician, depending on state pharmacy laws, just as pharmacists can do with generics.
The current approach protects patients. The proposed legislation, however, would order the FDA to declare new biosimilars interchangeable with their reference drugs without further review. Some politicians might expect this change to simply eliminate red tape, but it could also cause harm. If any biosimilar could be declared interchangeable without evaluation, there could be an increased risk to patient safety from automatic substitution.
Or, regulators might respond to the law by applying an even higher standard before approving new biosimilars. This could delay access to cheaper drugs.
Biosimilars can still deliver significant benefits to patients without being deemed interchangeable. The FDA approved Truxima as a noninterchangeable biosimilar to treat non-Hodgkin’s lymphoma.
But if the proposed law had been in place, this biosimilar treatment may not have reached patients on the same timeline. Regulators may have forced the developers behind these treatments to invest more time and resources into proving that their medicines met the higher interchangeability standard.
It’s in the best interests of patients and Colorado’s medical innovators to ensure these biosimilars can swiftly enter the market, even if they might not initially be considered interchangeable. Our state maintains a robust biologic and biosimilar development ecosystem, primarily at Colorado State University.
As we debate how to reduce the high cost of many drugs, our efforts should be focused on the areas that can really make a difference. Neither of these two bills, for example, would protect patients from the anticompetitive behavior of pharmacy benefit managers, which are often the source of unnecessarily high prices. pharmacy benefit managers restrict access to less-expensive biosimilars by excluding them from insurers’ lists of covered drugs to maximize their profits. In recent years, pharmacy benefit managers did just that with biosimilars for insulin and with those for Humira, which treats Crohn’s disease.
The goals behind the two bills are good ones — increase patient access to biosimilars, cut red tape, and lower costs — but the proposed laws now making their way toward legislative committees would accomplish none of these things. Instead, they would slow the pace of medical innovation and send a chill through the biopharmaceutical industry across the country and here in Colorado.
For decades, our state’s booming life sciences industry has made it a magnet for talent and investment. According to a report by CBRE, a commercial real estate group, rapid growth of life sciences jobs in Colorado has put the state in the top ten for life sciences research talent. That talent is now attracting more than $1 billion in new public and private funding yearly.
Colorado’s bioscience sector comprises more than 700 businesses and organizations, supports 38,000 jobs, and generates more than $12 billion in annual economic output. The state is home to 34 federal research labs, including some at state universities. Since 2004, more than 7,000 clinical trials have been conducted in the state. And between 2018 and 2021, more than 3,400 life sciences patents were issued here.
These two bills would put this dynamism at risk. They would make life sciences research, development, and manufacturing more difficult and less profitable. Our competitive edge would dull, investment would dry up, and jobs would disappear. And for those costs, patients would also suffer the unintended consequences of this legislation which puts patient safety at risk in the short term, and affects all of us in the long term by slowing the drug discovery pipeline.
Peggy Dennis, a Colorado native and resident of Denver, is an eight-year survivor of nonsmall cell lung cancer who has participated in several clinical trials and is an advocate for patient rights and research, with the Exon 20 Group of ICAN, International Cancer Advocacy Network.









